Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 9051 - 9075 of 9162 in total
Investigational
Investigational
Investigational
A MET receptor tyrosine kinase inhibitor.
Investigational
Investigational
TBC3711 is a next-generation endothelin antagonist that is being studied through oral and intravenous formulations by Encysive Pharmaceuticals.
Investigational
Investigational
Experimental
Investigational
Matched Iupac: … carbamoyl-30-(carbamoylmethyl)-24,45-bis(carboxymethyl)-48-(hydroxymethyl)-27-[(4-hydroxyphenyl)methyl]-21
Investigational
Investigational
A P2Y12 inhibitor and platelet aggregation inhibitor.
Investigational
Investigational
Investigational
Investigational
FT516 is an investigational and engineered off-the-shelf natural killer (NK) cell therapy originating from induced pluripotent stem cells (iPSC). This compound expresses a high-affinity 158V, CD16 (hnCD16) Fc receptor that has an enhanced binding ability to tumor-targeting antibodies, and is resistant to downregulation. FT516 is currently being tested against acute...
Investigational
AR-9281 inhibits soluble epoxide hydrolase.
Investigational
Investigational
Investigational
Investigational
RAV12 is investigated for use/treatment in solid tumors. RAV12 is a solid. RAV12 is a chimeric antibody that recognizes RAAG12, an N-linked carbohydrate antigen found on gastric, colon, pancreatic, prostate, ovarian, breast, and kidney cancer cells.
Investigational
Investigational
Investigational
Investigational
Investigational
Displaying drugs 9051 - 9075 of 9162 in total